Cost effectiveness of replacing recombinated interferon α-2b with its pegylated form in combination with ribavirin for the therapy of chronic HCV infection in Poland

Advances in Clinical and Experimental Medicine

Volumn 15, Issue 3, 2006, Pages 453-462

  Simon, Krzysztof ^a   Gładysz, Andrzej ^a   Rotter, Katarzyna ^a   Rymer, Weronika ^a   Smoliński, Patryk ^a   Inglot, Małgorzata ^a   Władysiuk Blicharz, Magdalena ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b HTA consulting ^*

Author keywords

Economic analysis; HCV infection; Pegylated interferon alpha 2b; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CALCULATION; COHORT ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; ECONOMIC EVALUATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; POLAND; PROBABILITY; PROFIT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 33746143300     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. State Department of Hygiene. Chief Sanitary Inspectorate: Yearly Reports 1999-2002 on the incidence of infectious diseases and cases of chemical compound poisoning reported in 2000-2002. Warsaw 2000-2003.
2. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002, 36, S35-46.
3. Yano M, Kumada H, Kage M et al.: The long term pathological evolution of chronic hepatitis C. Hepatology 1996, 23, 1334-1340.
4. Kim WR: The burden of hepatitis C in the United States. Hepatology 2002, 36, P30-34.
5. Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future. Oncology 2002, 62, 8-17.
6. Craxi A, Licata A: Clinical Trial Results of Peginterferons in Combination with Ribavirin. Sem Liv Dis 2003, 23, Suppl. 1, 35-46.
7. Thomas H, Foster G, Platis D: Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003, 39, P93-98.
8. Pawlotsky JM: Use and interpretation of virological tests for hepatitis C. Hepatology 2002, 36, Suppl 1, P65-P73.
9. Herrmann E, Neumann AU, Schmidt JM, Zeuzem: Hepatitis C virus kinetics. Antivir Ther 2000, 5, 85-90.
10. Zeuzem S, Herrmann E, Lee JH et al.: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. Gastroenterology 2001, 120, 1438-1447.
11. Fontana RJ, Lok ASF: Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002, 36, Suppl 1, P57-P64
12. Gordon SC, Fang JWS, Silverman AL, McHutchinson JG, Albrecht JK: The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000, 32, 400-404.
13. Dienstag JL: The role of liver biopsy in chronic hepatitis C. Hepatology 2002, 36, Suppl 1, P152-P160.
14. Manns MP, McHutchinson JG, Gordon SC et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358, 958-965.
15. Lindsay K, Trepo CH, Heintages T: A randomized, double blind trial comparing pegylated interferon alpha 2b to interferon alpha 2b an initial treatment for chronic hepatitis C. Hepatology 2001, 34, 395-404.
16. Hadziyannis SJ, Sette H, Morgan TR et al.: Peginterferon-alfa2a and Ribavirin Combination Therapy in Chronic Hepatitis C. Ann Int Med 2004, 140, 5, 346-355.
17. Lamb MW, Martin NE: Weight-Based Versus Fixed Dosing of Peginterferon (40 kDa) Alfa-2a. Ann Pharmacother 2002, 36, 933-935.
18. Davis GL, Wong JB, McHutchinson JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38, 645-652.
19. Fried MW, Shiffman ML, Reddy KR et al.: Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347, 975-982.
20. Juszczyk J, Białkowska J, Bolewska B et al.: Pegylated interferon alfa-2b alfa ribavirin in treatment of chronic hepatitis C. Pol Merk Lek 2004, XVI, 94, 353-357.
21. Poynard T, Ratziu V, McHutchinson J et al.: Effect of Treatment with Peginterferon or Interferon alfa-2b and Ribavirin on Steatosis in Patients Infected With Hepatitis C. Hepatology 2002, 38, 1, 75-85.
22. Dumortier J, Scoazec J-Y, Chevalier P, Boillot O: Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004, 40, 4, 669-674.
23. McHutchinson JG, Patel K: Future therapy of hepatitis C. Hepatology 2002, 36, Suppl 1, P245-P252.
24. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13, 322-338.
25. Beck JR, Pauker SG: The Markov process in medical prognosis. Med Decis Making 1983, 3, 419-458.
26. Sagemeister M, Renner EL., Mullhaupt B, Wong JB: Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 2002, 14, 25-34.
27. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ: Empirically-calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002, 156, 761-773.
28. Fattowich G, Guistina G, Degas F: Morbidity and mortality in compensated liver cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112, 463-472.
29. Wong JB, Bennett WG, Koff RS, Pauker SG: Pretreatment Evaluation of Chronic Hepatitis C: Risks, Benefits and Costs. JAMA 1998, 280, 2088-2093.
30. Younossi ZM, Singer ME, McHutchinson JG et al.: Cost effectiveness of interferon alpha 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999, 30, 5, 1318-1324.
31. Di Bisceglie AM, Hoofnagle JH: Optimal therapy of hepatitis C. Hepatology 2002, 36, Suppl 1, P121-P127.
32. Buti M, Casado MA, Fosbrook L et al.: Cost effectiveness of combination therapy for naïve patients with chronic hepatitis C. J Hepatol 2000, 33, 4, 651-658.
33. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ: Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patients Population. JAMA 2003, 290(2), 228-237.
34. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth B, Manns MP, McHutchinson JG, Wong JB: Cost-effectiveness of Peg-interferon alpha 2b plus ribavirin compared with interferon alpha 2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003, 52, 3, 425-432.
35. Wong JB, Davis G, McHutchinson JG, Manns M, Albrecht J: Economic and Clinical Effects of Evaluating Rapid Viral Response to Peginterferon Alfa-2b plus Ribavirin for the Initial Treatment of Chronic Hepatitis C. Am J Gastroenterology 2003, 98, 1, 2355-2362.
36. Orlewska E, Zaborowski P: Costs and effects of combined therapy with pegylated interferon alpha-2a with ribavirin in comparison with standard combined therapy with interferon alpha 2b with ribavirin in chronic hepatitis C in adults in Poland. Pharmacoeconomics 2003, 4, 3-15.
37. Nuijten MJC: Data management in modeling studies: the selection of data sources. Pharmacoeconomics 1998, 3, 305-316.
38. Wright J, Weinstein M: Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 1998, 339, 380-386.
39. Carithers RL Jr, Sugano D, Bayliss M: Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci 1996, 41, Suppl. 12, P75-80.
40. Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998, 27, 1, 209-212.
41. Bonkovsky HL, Woolley JM: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999, 29, 1, 264-270.
42. Siebert U, Ravens-Sieberer U, Greiner W et al.: Patients-based health related quality of life in different health stages of chronic hepatitis C. Hepatology 2001, 44, pt 2, 222A.